Effect of pegylated interferon β-1a therapy on the liver fibrosis in chronic hepatitis C: A semi-quantitative analysis

National Medical Journal of China

Volumn 88, Issue 2, 2008, Pages 96-100

  Rao, Hui Ying ^a   Li, Jing ^b   Zhang, Lan Fang ^b   Chen, Huan Yong ^b   Zhu, Li Min ^b   Wei, Lai ^b   Sun, Yan ^b   Wang, Hao ^b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b NONE

Author keywords

Collagen; Hepatitis C, chronic; Interferon beta; Liver cirrhosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 3; PEGINTERFERON; PEGINTERFERON BETA1A; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER FIBROSIS; MALE; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SEX DIFFERENCE; STELLATE CELL; TREATMENT DURATION;

ACTINS; ADULT; ANTIVIRAL AGENTS; COLLAGEN TYPE III; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-BETA; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MUSCLE, SMOOTH; RIBAVIRIN; TREATMENT OUTCOME;

EID: 41549099733     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis, 2004, 24 Suppl 2:3-8.
2. Chinese source.
3. Poynard T, Yuen MF, Ratziu V, et al. Viral hepatitis C. Lancet, 2003, 362: 2095-2100.
4. Kim AI, Saab S. Treatment of hepatitis C. Am J Med, 2005, 118: 808-815.
5. Kaito M, Yasui-Kawamura N, Iwasa M, et al. Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C. Hepatogastroenterology, 2003, 50: 775-778.
6. Pellicano R, Palmas F, Cariti G, et al. Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol, 2002, 14: 1377-1382.
7. Chinese source.
8. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest, 2005, 115: 209-218.
9. Chinese source.
10. Chinese source.
11. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatology, 1995, 22: 696-699.
12. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology, 1981, 1: 431-435.
13. Schmitt-Graff A, Kruger S, Bochard F, et al. Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol, 1991, 138: 1233-1242.
14. Luxon BA, Grace M, Brassard D, et al. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther, 2002, 24: 1363-1383.
15. Perry CM, Jarvis B. Spotlight on peginteferon α-2a (40KD) in chronic hepatitis C. BioDrugs, 2002, 16: 213-217.
16. Camma C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology, 2004, 39:333-342.
17. Cornberg M, Hadem J, Herrmann E, et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol, 2006, 44:291-301.
18. Arima M, Terao H, Kashima K, et al. Regression of liver fibrosis in cases of chronic liver disease type C: quantitative evaluation by using computed image analysis. Intern Med, 2004, 43: 902-910.
19. De Torres M, Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol, 2003, 2:5-11.
20. Sakaida I, Nagatomi A, Hironaka K, et al. Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy. Am J Gastroenterol, 1999, 94: 489-496.